We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

378 hedge funds and large institutions have $8.35B invested in Royalty Pharma in 2024 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 141 increasing their positions, 127 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

222% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $4.19M

11% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 127

1.94% more ownership

Funds ownership: 68.15% → 70.09% (+1.9%)

7% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 56

0% more funds holding

Funds holding: 378 → 378 (0)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

10% less capital invested

Capital invested by funds: $9.24B → $8.35B (-$885M)

Holders
378
Holders Change
–
Holders Change %
0%
% of All Funds
5.46%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
60
Increased
141
Reduced
127
Closed
56
Calls
$13.5M
Puts
$4.19M
Net Calls
+$9.31M
Net Calls Change
+$4.69M

Top Buyers

1
Swedbank
Swedbank
Sweden
+$300M
2
BlackRock
BlackRock
New York
+$50.2M
3
BGIM
Brandywine Global Investment Management
Pennsylvania
+$45.4M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$29.5M
5
Invesco
Invesco
Georgia
+$29.5M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$159M
2
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$81.4M
3
Millennium Management
Millennium Management
New York
-$64.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$15.8M
5
CSS
Cubist Systematic Strategies
Connecticut
-$14.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
MAM
276
Martingale Asset Management
Massachusetts
$312K +$28.1K +1,013 +9%
GCGDR
277
Geo Capital Gestora de Recursos
Brazil
$307K -$2.2M -79,228 -87%
AA
278
ALPS Advisors
Colorado
$303K -$1.72K -62 -0.5%
NC
279
nVerses Capital
Florida
$301K +$316K +11,400 New
OFS
280
OneAscent Financial Services
Alabama
$296K +$87K +3,139 +39%
ALAM
281
Asahi Life Asset Management
Japan
$286K +$300K +10,830 New
IFWM
282
Institute for Wealth Management
Colorado
$270K – – –
FHB
283
First Hawaiian Bank
Hawaii
$267K – – –
CI Investments Inc
284
CI Investments Inc
Ontario, Canada
$265K -$41.1K -1,482 -13%
II
285
Inspire Investing
Idaho
$263K -$930K -33,538 -77%
VFA
286
Values First Advisors
Tennessee
$255K -$2.44K -88 -0.9%
C
287
Covestor
United Kingdom
$255K +$26.1K +941 +11%
Mackenzie Financial
288
Mackenzie Financial
Ontario, Canada
$254K -$520K -18,742 -66%
Envestnet Portfolio Solutions
289
Envestnet Portfolio Solutions
Illinois
$254K +$267K +9,616 New
Acadian Asset Management
290
Acadian Asset Management
Massachusetts
$250K +$264K +9,516 New
SG Americas Securities
291
SG Americas Securities
New York
$241K -$2.45M -88,380 -91%
TMAM
292
Tokio Marine Asset Management
Japan
$240K – – –
VI
293
Versor Investments
New York
$236K -$849K -30,617 -77%
IMCOOI
294
Investment Management Corp of Ontario (IMCO)
Canada
$228K +$239K +8,633 New
William Blair & Company
295
William Blair & Company
Illinois
$222K +$233K +8,420 New
MAS
296
Meeder Advisory Services
Ohio
$217K +$25.7K +926 +13%
VI
297
Vestcor Inc
New Brunswick, Canada
$213K – – –
OWM
298
OneAscent Wealth Management
Alabama
$210K +$221K +7,963 New
PNC Financial Services Group
299
PNC Financial Services Group
Pennsylvania
$208K -$123K -4,425 -36%
Neuberger Berman Group
300
Neuberger Berman Group
New York
$205K -$376K -13,563 -64%
10 11
12
13 14

RPRX Hedge Fund Activity: Q2 2024 in Review

378 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2024, worth a combined $8.35B — down 9.6% from $9.24B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new RPRX positions and 56 closed out — a net gain of 4 holders — while 141 added to existing stakes and 127 trimmed.

The largest buyer was Swedbank, opening a new position worth an estimated $300M. The largest seller was Fidelity Investments, cutting an estimated $159M.

  • 378 institutional investors held Royalty Pharma (RPRX) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $8.35B of Royalty Pharma stock for Q2 2024, down 9.6% quarter-over-quarter.
  • 60 funds opened new Royalty Pharma positions in Q2 2024 and 56 closed out, a net change of +4 holders.
  • The largest Royalty Pharma buyer in Q2 2024 was Swedbank, an estimated $300M added.
  • The largest Royalty Pharma seller in Q2 2024 was Fidelity Investments, an estimated $159M sold.

Based on aggregated 13F filings for Q2 2024.